Accelerate.EU Elevating the Future of Cancer care with Alpha Theranostics
- Coordinator
- Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules Bordet, Belgium
- Runs
- 1 October 2024 to 30 September 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €16.1m
- Partners
- 17 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101173001
What the project is doing
In the project's own words, from its summary on CORDIS.
Accelerate. EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211. A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects. Accelerate. EU's core objectives are:Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients.•Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU.•Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durabilityAccelerate.
EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers. The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics. Accelerate. EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients. Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.
EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules Bordet | Anderlecht | Belgium | Coordinator |
| Ion Beam Applications SA | Ottignies Louvain La Neuve | Belgium | Participant |
| Studiecentrum Voor Kernenergie / Centre D'etude De L'energie Nucleaire | Bruxelles / Brussel | Belgium | Participant |
| The Oncidium Foundation | Bruxelles | Belgium | Participant |
| Universite Libre De Bruxelles | Bruxelles | Belgium | Participant |
| Forschungszentrum Julich GmbH | Julich | Germany | Participant |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Tetrakit Technologies Aps | Kobenhavn | Denmark | Participant |
| Fundacion Centro De Tecnologias De Interaccion Visual Y Comunicaciones Vicomtech | Donostia San Sebastian | Spain | Participant |
| Groupement Interet Public Arronax | Saint Herblain | France | Participant |
| Institut De Cancerologie De L'ouest | Angers | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Narodowe Centrum Badan Jadrowych | Otwock | Poland | Participant |
| Universidade De Coimbra | Coimbra | Portugal | Participant |
| Lablogic Systems Limited | Sheffield | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI